A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Daxdilimab Subcutaneous Injection in Adult Participants With Inadequately Controlled Dermatomyositis or Anti-synthetase Inflammatory Myositis
Latest Information Update: 23 Jul 2025
At a glance
- Drugs Daxdilimab (Primary)
- Indications Dermatomyositis; Myositis
- Focus Proof of concept; Therapeutic Use
- Sponsors Amgen; Horizon Therapeutics plc
Most Recent Events
- 11 Jul 2025 Status changed from active, no longer recruiting to completed.
- 01 Oct 2024 Planned End Date changed from 22 May 2027 to 2 Oct 2025.
- 01 Oct 2024 Planned primary completion date changed from 30 Oct 2026 to 12 Mar 2025.